| Disease | VOLUNTEERS.
CONCLUSION, WITHIN THE CONTEXT OF THE SPECIFIC GB PRODUCT USED DURING THIS INVESTIGATION, THE CONCOMITANT USE OF GB AND DIGOXIN DID NOT APPEAR TO HAVE ANY SIGNIFICANT EFFECT ON THE PHARMACOKINETICS OF ORALLY ADMINISTERED DIGOXIN IN HEALTHY
ADDITIONALLY, NO SIGNIFICANT DIFFERENCE BETWEEN THERAPIES WAS OBSERVED WITH RESPECT TO C-MAX, T-MAX OR CL-0. IN SIX SUBJECTS,K-E AND T-1/2 WERE ABLE TO BE DETERMINED. THESE PARAMETERS ALSO DID NOT DIFFER SIGNIFICANTLY BETWEEN TREATMENTS. IN
BLOOD SAMPLES WERE COLLECTED FOR DIGOXIN PLASMA CONCENTRATION DETERMINATION. NO SIGNIFICANT DIFFERENCE BETWEEN TREATMENTS WAS OBSERVED WITH RESPECT TO AUC 0-INFINTY (DIGOXIN ALONE: 21.0+-8.6[NG/ML]XH:DIGOXIN + GB: 25.6+- 13.2{NG/ML]XH).
WEEK PRIOR TO EACH STUDY PHASE, HALF OF THE VOLUNTEERS WERE RANDOMLY INTIATED ON GB THERAPY, 80 MG THREE TIMES DAILY, THAT CONTINUED UNTILL THE END OF THE STUDY PHASE. IMMEDIATELY PRIOR TO AND FOR 36 HRS FOLLOWING DIGOXIN INGESTION, MULTIPLE
ANOPEN-LABELED,RANDOMIZED, CROSSOVER TRIAL WAS CONDUCTED IN 8 HEALTHY HUMAN VOLUNTEERS TO DETERMINE IF GINKGO BILOBA (GB) ALSO ALTERS THE PHARMACOKINETICS OF DIGOXIN. ON TWO OCCASIONS SEPARATED BY 2 WKS, SUBJECTS INGESTED DIGOXIN,0.5 MG. ONE |